FPMI (FluoroPharma Medical) Effective Interest Rate on Debt %: 13.68% (As of Dec. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is FluoroPharma Medical Effective Interest Rate on Debt %?

FluoroPharma Medical FPMI Effective Interest Rate on Debt % is 13.68% as of Dec. 2016.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. FluoroPharma Medical's annualized positive value of Interest Expense for the quarter that ended in Dec. 2016 was $0.78 Mil. FluoroPharma Medical's average total debt for the quarter that ended in Dec. 2016 was $5.73 Mil. Therefore, FluoroPharma Medical's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2016 was 13.68%.


FluoroPharma Medical  (OTCPK:FPMI) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


FluoroPharma Medical Effective Interest Rate on Debt % Related Terms


FluoroPharma Medical Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for FluoroPharma Medical's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FluoroPharma Medical Effective Interest Rate on Debt % Chart

FluoroPharma Medical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 4.90 26.98 24.81

FluoroPharma Medical Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.78 34.01 35.02 15.47 13.68

FPMI vs HSTC, OBMPD, GOVX: Effective Interest Rate on Debt % Comparison

For the Biotechnology subindustry, FluoroPharma Medical's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FluoroPharma Medical Effective Interest Rate on Debt % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FluoroPharma Medical's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where FluoroPharma Medical's Effective Interest Rate on Debt % falls into.



FluoroPharma Medical Effective Interest Rate on Debt % Calculation

FluoroPharma Medical's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2016 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2015 )+Total Debt  (A: Dec. 2016 ))/ count )
=-1  *  -1.262/( (4.349+5.825)/ 2 )
=-1  *  -1.262/5.087
=24.81 %

where

FluoroPharma Medical's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2016 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2016 )+Total Debt  (Q: Dec. 2016 ))/ count )
=-1  *  -0.784/( (5.635+5.825)/ 2 )
=-1  *  -0.784/5.73
=13.68 %

where

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2016) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 13.68% mean?
FluoroPharma Medical (FPMI) has a Effective Interest Rate on Debt % of 13.68% as of Dec. 2016. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on FluoroPharma Medical and its competitors.
Is FluoroPharma Medical's Effective Interest Rate on Debt % too high?
FluoroPharma Medical's current Effective Interest Rate on Debt % is 13.68%.
How does FluoroPharma Medical's Effective Interest Rate on Debt % compare to HSTC and OBMPD?
FluoroPharma Medical's Effective Interest Rate on Debt % of 13.68% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on FluoroPharma Medical and its competitors. FluoroPharma Medical's current Effective Interest Rate on Debt % is 13.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FluoroPharma Medical stock overvalued right now?
FluoroPharma Medical (FPMI) has a current Effective Interest Rate on Debt % of 13.68%. The current Effective Interest Rate on Debt % is 13.68%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For FluoroPharma Medical (FPMI), the current Effective Interest Rate on Debt % is 13.68% as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

FluoroPharma Medical Business Description

Address 701 South Carson Street, Suite 200, Carson City, NV, USA, 89701
FluoroPharma Medical Inc is a us-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.